Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04789460
  4. Details
NCT04789460 Clinical Trial

Relationship Between Potential Predictors and Mortality in COVID-19 Patients ın Turkey

Covid19 Clinical Trial

Official title:
Relationship Between Potential Predictors and Mortality in COVID-19 Patients in Turkey: A New Prognostic Model

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04789460
Other study ID # TURKEYPROMOD
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 5, 2021
Est. completion date March 28, 2021

Study information
Verified date May 2021
Source Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the investigators planned to examine the laboratory characteristics of patients hospitalized with the diagnosis of Covid-19 and to investigate their relationship with mortality.

Description:

SARS-CoV-2 infection is effective in many countries and has caused pandemics. It is observed that it affects patients in a wide spectrum in terms of their clinical features worldwide. It is known that age, gender, and comorbidity play an important role in the course of the disease. Although mortality rates vary from country to country, there is no clear information due to the fact that the pandemic has not yet ended. In this study, the investigators planned to examine the laboratory characteristics of patients hospitalized with the diagnosis of Covid-19 and to investigate their relationship with mortality in Istanbul city which is the most affected by the pandemic in Turkey

Recruitment information / eligibility
Status Completed
Enrollment 816
Est. completion date March 28, 2021
Est. primary completion date March 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients who are 18 years of age and older, positive for SARS-CoV-2 PCR test and / or Covid-19 disease findings on CT will be included in the study. Exclusion Criteria: - Patients with negative SARS-CoV-2 PCR test, pneumonia on CT but not given Covid-19 treatment by not considering Covid-19 by their doctor will not be included.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Turkey SBU Sultan Abdulhamid Han Istanbul Asia

Sponsors (1)
Lead Sponsor Collaborator
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary mortality rate up to 30 days after discharge up to 30 days
Secondary need for intensive care unit rate need for intensive care unit during hospitalization up to 30 days
Secondary length stay in hospital number of length stay in hospital up to 30 days
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3